Phenoxybenzamine
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Phenoxybenzamine.png | |
| Phenoxybenzamine
| |
| Systematic (IUPAC) name | |
| N-benzyl-N-(2-chloroethyl)-1-phenoxy-propan-2-amine | |
| Identifiers | |
| CAS number | |
| ATC code | C04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C18H22ClNO |
| Mol. mass | 303.826 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 24 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C (U.S.) |
| Legal status | |
| Routes | Oral |
Phenoxybenzamine (marketed under the trade name Dibenzyline) is a non-specific, irreversible alpha blocker used in the treatment of hypertension, and specifically that caused by pheochromocytoma. It has a slower onset and a longer lasting effect compared with other alpha blockers. It was also the first alpha blocker to be used for treatment of benign prostatic hyperplasia,[1] although it is currently seldom used for that indication due to an unfavourable side effects profile.
Pharmacology
Phenoxybenzamine is used as an anti-hypertensive due to its efficacy in reducing the vasoconstriction caused by adrenaline and noradrenaline. Phenoxybenzamine forms a permanent covalent bond with adrenergic receptors. Based on what we know about the structures of these receptors, it likely involves attack by the cysteine at position 3.36 in transmembrane helix 3 to form a stable linkage.[1] Thus, it remains permanently bound to the receptor, preventing adrenaline and noradrenaline from binding. This causes vasodilatation in blood vessels, due to its antagonistic effect at the alpha-1 adrenoceptor found in the walls of blood vessels, resulting in a drop in blood pressure.
It will also affect the alpha 1 and 2 receptors found in the nervous system, where this will reduce sympathetic activity. This is due to its effect on the postsynaptic membrane adrenoceptors in the second synapse of the sympathetic nervous pathway, and will therefore reduce the 'fight or flight' output of the sympathetic nervous system. This results in further general vasodilation, pupil constriction, an increase in GI tract motility and secretions, and glycogen synthesis.
It also has partial agonist/antagonist properties at the serotonin 5-HT2A receptor.
References
- Day, M.D. (1979). Autonomic Pharmacology Experimental and Clinical Aspects. Churchill Livingstone.
- Bullock, S. Galbraith, A. Hunt, B. Manias, E. and Richards, A. (1999). Fundamentals of Pharmacology. Pearson Education Limited publishing as Prentice Hall.
Peripheral vasodilators (C04) | |
|---|---|
| Imidazoline derivatives | Phentolamine - Tolazoline |
| Niacin and derivatives | Niacin |
| Purine derivatives | Pentoxifylline |
| Ergot alkaloids | Ergoloid- Nicergoline |
| Other peripheral vasodilators | Phenoxybenzamine - Vincamine - Naftidrofuryl |
